262 related articles for article (PubMed ID: 32561536)
1. Identification of the Cryptic HLA-I Immunopeptidome.
Erhard F; Dölken L; Schilling B; Schlosser A
Cancer Immunol Res; 2020 Aug; 8(8):1018-1026. PubMed ID: 32561536
[TBL] [Abstract][Full Text] [Related]
2. Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.
Gloger A; Ritz D; Fugmann T; Neri D
Cancer Immunol Immunother; 2016 Nov; 65(11):1377-1393. PubMed ID: 27600516
[TBL] [Abstract][Full Text] [Related]
3. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
Freudenmann LK; Marcu A; Stevanović S
Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
[TBL] [Abstract][Full Text] [Related]
4. A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients.
Gallou C; Rougeot A; Graff-Dubois S; Kosmatopoulos K; Menez-Jamet J
Oncotarget; 2016 Sep; 7(37):59417-59428. PubMed ID: 27506946
[TBL] [Abstract][Full Text] [Related]
5. Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens.
Bassani-Sternberg M
Methods Mol Biol; 2018; 1719():209-221. PubMed ID: 29476514
[TBL] [Abstract][Full Text] [Related]
6. RBM-MHC: A Semi-Supervised Machine-Learning Method for Sample-Specific Prediction of Antigen Presentation by HLA-I Alleles.
Bravi B; Tubiana J; Cocco S; Monasson R; Mora T; Walczak AM
Cell Syst; 2021 Feb; 12(2):195-202.e9. PubMed ID: 33338400
[TBL] [Abstract][Full Text] [Related]
7. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
[TBL] [Abstract][Full Text] [Related]
8. Quantification of HLA-DM-Dependent Major Histocompatibility Complex of Class II Immunopeptidomes by the Peptide Landscape Antigenic Epitope Alignment Utility.
Álvaro-Benito M; Morrison E; Abualrous ET; Kuropka B; Freund C
Front Immunol; 2018; 9():872. PubMed ID: 29774024
[TBL] [Abstract][Full Text] [Related]
9. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
10. Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors.
Marcu A; Schlosser A; Keupp A; Trautwein N; Johann P; Wölfl M; Lager J; Monoranu CM; Walz JS; Henkel LM; Krauß J; Ebinger M; Schuhmann M; Thomale UW; Pietsch T; Klinker E; Schlegel PG; Oyen F; Reisner Y; Rammensee HG; Eyrich M
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599019
[TBL] [Abstract][Full Text] [Related]
11. Nowhere to hide: unconventional translation yields cryptic peptides for immune surveillance.
Starck SR; Shastri N
Immunol Rev; 2016 Jul; 272(1):8-16. PubMed ID: 27319338
[TBL] [Abstract][Full Text] [Related]
12. SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity.
Park J; Talukder AH; Lim SA; Kim K; Pan K; Melendez B; Bradley SD; Jackson KR; Khalili JS; Wang J; Creasy C; Pan BF; Woodman SE; Bernatchez C; Hawke D; Hwu P; Lee KM; Roszik J; Lizée G; Yee C
Cancer Immunol Res; 2017 Aug; 5(8):618-629. PubMed ID: 28630054
[TBL] [Abstract][Full Text] [Related]
13. [HLA-restricted cancer-specific killer T cells].
Harada M; Itoh K
Nihon Rinsho; 2005 Apr; 63 Suppl 4():579-84. PubMed ID: 15861714
[No Abstract] [Full Text] [Related]
14. A large fraction of HLA class I ligands are proteasome-generated spliced peptides.
Liepe J; Marino F; Sidney J; Jeko A; Bunting DE; Sette A; Kloetzel PM; Stumpf MP; Heck AJ; Mishto M
Science; 2016 Oct; 354(6310):354-358. PubMed ID: 27846572
[TBL] [Abstract][Full Text] [Related]
15. Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction.
Abelin JG; Harjanto D; Malloy M; Suri P; Colson T; Goulding SP; Creech AL; Serrano LR; Nasir G; Nasrullah Y; McGann CD; Velez D; Ting YS; Poran A; Rothenberg DA; Chhangawala S; Rubinsteyn A; Hammerbacher J; Gaynor RB; Fritsch EF; Greshock J; Oslund RC; Barthelme D; Addona TA; Arieta CM; Rooney MS
Immunity; 2019 Oct; 51(4):766-779.e17. PubMed ID: 31495665
[TBL] [Abstract][Full Text] [Related]
16. Epitope distribution in ordered and disordered protein regions - part A. T-cell epitope frequency, affinity and hydropathy.
Mitić NS; Pavlović MD; Jandrlić DR
J Immunol Methods; 2014 Apr; 406():83-103. PubMed ID: 24614036
[TBL] [Abstract][Full Text] [Related]
17. Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides.
Huang D; Zhu X; Ye S; Zhang J; Liao J; Zhang N; Zeng X; Wang J; Yang B; Zhang Y; Lao L; Chen J; Xin M; Nie Y; Saw PE; Su S; Song E
Nature; 2024 Jan; 625(7995):593-602. PubMed ID: 38093017
[TBL] [Abstract][Full Text] [Related]
18. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.
Bassani-Sternberg M; Pletscher-Frankild S; Jensen LJ; Mann M
Mol Cell Proteomics; 2015 Mar; 14(3):658-73. PubMed ID: 25576301
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor vaccination in heterozygous congenic F1 mice: presentation of tumor-associated antigen by the two parental class I alleles.
Carmon L; Tzehoval E; Tirosh B; el-Shami KM; Bar-Haim E; Vadai E; Feldman M; Eisenbach L
J Immunother; 2000; 23(3):344-52. PubMed ID: 10838663
[TBL] [Abstract][Full Text] [Related]
20. Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides.
Kessler JH; Mommaas B; Mutis T; Huijbers I; Vissers D; Benckhuijsen WE; Schreuder GM; Offringa R; Goulmy E; Melief CJ; van der Burg SH; Drijfhout JW
Hum Immunol; 2003 Feb; 64(2):245-55. PubMed ID: 12559627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
